Immunovant (NASDAQ:IMVT) Releases Earnings Results, Misses Estimates By $0.12 EPS

Immunovant (NASDAQ:IMVT) posted its earnings results on Thursday. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.12), FiscalAI reports. The company had revenue of $7.09 million during the quarter, compared to analysts’ expectations of $7.09 million. During the same quarter in the previous year, the business earned ($0.71) earnings per share.

Here are the key takeaways from Immunovant’s conference call:

• Brexpiprazole’s potential dermatomyositis launch remains on track for late September following priority review, with commercial and patient-support teams in place. Management emphasized a “slow and steady” rollout focused on building access and a broader multi-indication franchise rather than maximizing early sales.
• Roivant has begun enrolling the phase III cutaneous sarcoidosis study after strong phase II results, while the lichen planus program is also enrolling well. Top-line readouts are expected in the second half of 2026 for brexpocitinib in non-infectious uveitis and povorcitinib in PH-ILD, with additional proof-of-concept data in cutaneous lupus.
• Roivant received approximately $950 million from its Moderna settlement, including roughly $772 million attributable to Genevant and Arbutus. Additional potential proceeds include about $1.3 billion from the ongoing ’498 appeal and further litigation against Pfizer and BioNTech.
• The company reported nearly $4 billion in cash before the settlement proceeds and repurchased approximately $200 million of shares during the quarter. Management said buybacks will continue under existing authorizations, citing attractive share-retirement economics.
• Management highlighted substantial execution and clinical risk in the upcoming catalysts: PH-ILD’s key question is whether povorcitinib’s pulmonary vascular effects translate from PAH, while placebo-response variability remains a concern for the NIU study. Roivant expects to provide a fuller update on difficult-to-treat rheumatoid arthritis after randomized-withdrawal data and an FDA discussion later this year.

Immunovant Trading Up 0.5%

Shares of NASDAQ IMVT traded up $0.21 during trading hours on Friday, reaching $39.95. The stock had a trading volume of 906,196 shares, compared to its average volume of 922,481. The firm has a market cap of $8.25 billion, a price-to-earnings ratio of -14.17 and a beta of 0.77. Immunovant has a fifty-two week low of $14.32 and a fifty-two week high of $41.23. The firm has a 50-day moving average of $37.23 and a 200-day moving average of $30.59.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on IMVT shares. The Goldman Sachs Group increased their price objective on Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Guggenheim boosted their target price on Immunovant from $44.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. JPMorgan Chase & Co. upped their price target on Immunovant from $47.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday. Truist Financial increased their price target on shares of Immunovant from $23.00 to $30.00 and gave the company a “hold” rating in a research note on Friday, May 22nd. Finally, HC Wainwright raised their price objective on shares of Immunovant from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Immunovant has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Insider Activity at Immunovant

In other Immunovant news, Director Andrew J. Fromkin sold 221,951 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $33.51, for a total value of $7,437,578.01. Following the completion of the sale, the director owned 74,382 shares in the company, valued at approximately $2,492,540.82. The trade was a 74.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Melanie Gloria sold 17,714 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $38.31, for a total transaction of $678,623.34. Following the completion of the sale, the chief operating officer directly owned 224,393 shares of the company’s stock, valued at $8,596,495.83. The trade was a 7.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 324,810 shares of company stock valued at $11,350,166 over the last 90 days. 1.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. VARCOV Co. acquired a new stake in shares of Immunovant in the 4th quarter worth $404,000. Virtus Investment Advisers LLC increased its stake in shares of Immunovant by 41.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,069 shares of the company’s stock worth $256,000 after acquiring an additional 2,931 shares during the period. Kestra Advisory Services LLC purchased a new position in Immunovant during the fourth quarter worth about $228,000. Empowered Funds LLC raised its holdings in Immunovant by 4.5% during the fourth quarter. Empowered Funds LLC now owns 14,175 shares of the company’s stock worth $360,000 after purchasing an additional 610 shares in the last quarter. Finally, Oxford Asset Management LLP acquired a new stake in Immunovant in the second quarter valued at about $187,000. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.